Bausch Health Companies INC 10-Q quarterly reports

Bausch Health Companies Inc. reported a 13% increase in Q2 2026 revenue to $2.85 billion, driven by pricing and acquisitions, but a significant goodwill impairment led to a net loss attributable to the company of $1.17 billion for the six-month period.

Bausch Health reports strong Q3 2025 revenue growth of 7% to $2.681 billion, driven by Bausch + Lomb, Salix, and Solta Medical segments, alongside significant debt refinancing activities.

Bausch Health Companies Inc. reported a significant turnaround to net income in Q2 2025, driven by revenue growth and successful debt refinancing efforts, despite rising interest expenses and ongoing legal challenges.

Bausch Health Companies Inc. announces its Q1 2025 financial results, highlights debt refinancing efforts, and addresses ongoing legal proceedings, including Xifaxan patent litigation.

Bausch Health Companies Inc. saw a revenue increase in Q3 2024, while also managing to reduce its net losses compared to the same period last year.

Bausch Health Companies Inc. reports an 11% increase in revenue for the second quarter of 2024, driven by growth across all segments.

Bausch Health Companies Inc. reports a net loss of $64 million for Q1 2024, alongside a revenue increase of 11% year-over-year, as it continues to navigate strategic restructuring and legal challenges.